CAAS Capital Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

CAAS Capital Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$5.08K	Hold	75,000	–	–	﹤0.01%	455
2024 Q4	$3.56K	Hold	75,000	–	–	﹤0.01%	345
2024 Q3	$3.17K	Hold	75,000	–	–	﹤0.01%	416
2024 Q2	$3.37K	Hold	75,000	–	–	﹤0.01%	206
2024 Q1	$2.26K	Hold	75,000	–	–	﹤0.01%	489
2023 Q4	$4.5K	Hold	75,000	–	–	﹤0.01%	454
2023 Q3	$3.8K	Hold	75,000	–	–	﹤0.01%	611
2023 Q2	$3.76K	Hold	75,000	–	–	﹤0.01%	642
2023 Q1	$3.13K	Hold	75,000	–	–	﹤0.01%	669
2022 Q4	$5.99K	Hold	75,000	–	–	﹤0.01%	699
2022 Q3	$8K	Hold	75,000	–	–	﹤0.01%	748
2022 Q2	$13K	Buy	+75,000	New	+$16.3K	﹤0.01%	789

Other funds holding ASBPW

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

CAAS Capital Management's ASBPW Position: Q1 2025 in Review

CAAS Capital Management held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2025 at 75,000 shares worth $5.08K. The position accounts for ﹤0.01% of the portfolio, ranked #455.

CAAS Capital Management first reported a position in ASBPW in Q2 2022 and has held it in 12 quarters since. The position peaked at $13K in Q2 2022. 27 funds tracked by Wall St. Rank hold ASBPW as of Q1 2025.

CAAS Capital Management held 75,000 shares of Aspire Biopharma Warrant worth $5.08K as of Q1 2025.
CAAS Capital Management left its Aspire Biopharma Warrant share count unchanged in Q1 2025.
Aspire Biopharma Warrant made up ﹤0.01% of CAAS Capital Management's portfolio in Q1 2025, its #455 holding.
CAAS Capital Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 12 quarters since.
CAAS Capital Management's Aspire Biopharma Warrant position peaked at $13K in Q2 2022.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.